@ramiiny's GLP-1 weight loss story, fact-checked

What did @ramiiny actually say?

@ramiiny shared a personal story about secretly taking semaglutide (she calls it "ozempeck") one week before elective breast augmentation surgery in Brazil, without a prescription or medical supervision. She got it directly from a pharmacy, learned injection technique from YouTube, and her surgery was canceled when she disclosed this to her surgical team. Her core message: chasing thinness through shortcuts, without addressing mental health, does not produce lasting change.

She is not promoting semaglutide. She is explicitly warning against the uncritical hype around it. That distinction matters, and it is worth giving her credit upfront: this video is a cautionary story, not a sales pitch.

Does the science back this up?

On the surgical risk piece, she is correct, and the concern is serious enough that anesthesiologists have issued formal guidance on it. The American Society of Anesthesiologists (ASA) recommended in 2023 that patients hold GLP-1 receptor agonists before elective procedures specifically because of elevated aspiration risk.

GLP-1 drugs like semaglutide slow gastric emptying significantly. A 2023 case series published in Anaesthesia (Silveira et al., 2023) documented patients on GLP-1 agonists who had residual gastric contents under general anesthesia despite following standard fasting protocols. This creates a real risk of pulmonary aspiration, where stomach contents enter the lungs during intubation. Her surgeon canceling the procedure was not being "super mean," as she puts it. That decision was medically appropriate and possibly prevented a serious complication.

On the rebound weight gain point, she is also directionally correct. Multiple trials show that weight regained after stopping semaglutide is common without behavioral intervention, which directly supports her claim that "your mind still being in the same track" matters.

What did they get wrong (or right)?

She gets the surgical risk right, the mental health framing right, and the rebound risk roughly right. A few things deserve more precision.

First, she says she was "still hungry" and "still binging a lot" after her first dose, implying the drug did nothing. A single dose at the starting level, which is typically 0.25 mg for the first four weeks, is not designed to suppress appetite meaningfully. The therapeutic effect builds over months of dose escalation. Expecting appetite suppression after one shot is a misunderstanding of how the drug works, but she is telling a personal story, not a pharmacology lecture, so this is understandable rather than irresponsible.

Second, her claim that "two months later I would gain all the way back" is slightly overstated. The STEP 1 extension data (Wilding et al., 2022, Diabetes, Obesity and Metabolism) showed patients regained roughly two-thirds of lost weight within a year of stopping, not all of it within two months. The direction of her point is right; the timeline is compressed.

She does not make any dangerous dosing recommendations, does not promote a brand or product, and does not claim semaglutide treats any disease. That puts her well ahead of most GLP-1 content on this platform.

What should you actually know?

If you are on a GLP-1 receptor agonist and have any surgery scheduled, this is not a casual conversation to have. The ASA 2023 guidance recommends holding weekly injectables like semaglutide for at least one week before elective procedures, and daily formulations for the day of surgery. Your surgeon and anesthesiologist need to know. Full stop.

Beyond surgery, the broader point she is making about mental health and disordered eating is backed by clinical literature. Binge eating disorder has a documented prevalence of 3-5% in people seeking weight loss treatment (Grilo et al., 2013, Journal of Consulting and Clinical Psychology). Using a medication to suppress appetite without addressing compulsive eating patterns does not resolve the underlying behavior. Several studies on GLP-1 drugs specifically note that behavioral support improves long-term outcomes compared to medication alone.

• Never take any prescription medication, including semaglutide, without a licensed provider who knows your full medical history.
• Disclose all medications to your surgical team, even if you took them only once. The drug's half-life means timing matters.
• GLP-1 drugs work gradually over months of titration, not after a single injection.

Should you trust this video?

Yes, with appropriate calibration. @ramiiny is sharing lived experience, not clinical expertise, and she says as much: "I'm far far away from the patient." Her surgical story checks out scientifically. Her mental health message is well-supported. Where she simplifies, it is toward caution rather than recklessness. The content is honest, self-aware, and does not try to sell you anything. In a sea of GLP-1 content that does all three of those things badly, this one holds up reasonably well.